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Many lines of evidence indicate that the activity of
sebaceous glands can be modulated by neuropep-
tides. Direct evidence in man, however, is still miss-
ing. We show that SZ95 sebocytes, an immortalized
human sebaceous gland cell line, express receptors
for a-melanocyte-stimulating hormone. Reverse
transcription polymerase chain reaction with primers
against the ®ve melanocortin receptors and immuno-
¯uorescence studies using an antibody directed
against a peptide corresponding to the amino acids
2±18 of the human melanocortin-1 receptor disclosed
speci®c transcripts and immunoreactivity for
melanocortin-1 receptor in these cells. Melanocortin-
1 receptor expression was con®rmed in sebocytes of
normal human skin by immunohistochemistry. In
contrast, no immunostaining for the melanocortin-5
receptor could be detected in sebocytes in situ, in
accordance with the lack of speci®c transcripts for
this melanocortin receptor in SZ95 sebocytes. As
cytokines play an important role in the recruitment
of in¯ammatory cells in acne and related disorders
and a-melanocyte-stimulating hormone exerts
immunomodulatory effects in many other cell types,
we investigated the effect of a-melanocyte-stimulat-
ing hormone on interleukin-8 secretion by SZ95
sebocytes. Treatment with interleukin-1b resulted in
a marked increase in interleukin-8 release that was
partially blocked by coincubation with a-melano-
cyte-stimulating hormone in a dose-dependent
manner. Taken together, we show here that the mel-
anocortin-1 receptor is expressed in vitro and in situ
in human sebocytes. By modulating interleukin-8
secretion, a-melanocyte-stimulating hormone may
act as a modulator of in¯ammatory responses in the
pilosebaceous unit. Key words: a-melanocyte-stimulating
hormone/cell proliferation/cytokine/interleukin-8/sebaceous
gland/SZ95 sebocytes. J Invest Dermatol 118:533±539,
2002
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t is well established that the skin is a target organ and a
peripheral source for proopiomelanocortin (POMC)-derived
peptides (reviewed in BoÈhm and Luger, 2000; Slominski et
al, 2000). One of these peptides is a-melanocyte-stimulating
hormone (a-MSH), a tridecepeptide that is generated from
POMC by successive endoproteolytic cleavage through the action
of distinct prohormone convertases. During the last few years it has
become apparent that a-MSH can elicit many biologic effects
besides regulation of pigmentation. In monocytes a-MSH induces
interleukin-10 (IL-10), a potent suppressor of proin¯ammatory
cytokines (Bhardwaj et al, 1996). In mice, a-MSH is capable of
suppressing the contact hypersensitivity reaction by inducing
hapten-speci®c tolerance (Grabbe et al, 1996). In a mouse model
of experimentally induced cutaneous vasculitis, a-MSH also
suppresses endothelial damage and expression of distinct adhesion
molecules on dermal endothelial cells (SunderkoÈtter et al, 1999).
The diversity of these biologic effects of a-MSH are mediated by
speci®c receptors that are known as the melanocortin receptors
(MC-Rs) (reviewed in Cone et al, 1996). These receptors belong to
the super-family of G-protein-coupled receptors with seven
transmembrane domains whose engagement by the ligand results
in increased levels of intracellular cAMP. Until now, ®ve different
MC-Rs have been cloned (reviewed in Cone et al, 1996). The
individual MC-Rs differ in their tissue distribution and can be
discriminated from each other by their relative af®nities towards the
naturally occurring melanocortins a-, b-, and g-MSH and
adrenocorticotropic hormone (ACTH) as well as the synthetic
MSH analog [Nle4, D-Phe7]-MSH (reviewed in Cone et al, 1996).
The sebaceous gland has long been recognized as a target for
a-MSH (reviewed in Thody and Schuster, 1989; BoÈhm and Luger,
1998). Thody and coworkers reported that removal of the posterior
pituitary in the rat signi®cantly reduces the lipid secretion rates by
the preputial gland, a specialized lipid-producing organ (Thody and
Schuster, 1972). The lipotrophic substance responsible for this
effect was identi®ed as a-MSH (Thody and Schuster, 1973).
Further studies have revealed that daily treatment with a-MSH
resulted in a dose-dependent increase in sebum secretion of intact
rats (Thody et al, 1975). By means of in vivo binding studies with
iodinated [Nle4, D-Phe7]-MSH it was later shown that MSH
receptors were widely distributed in numerous glandular organs in
rodents (Tatro and Reichlin, 1987). Direct evidence for a biologic
activity of a-MSH on sebocytes in man, however, is still missing.
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In vitro, a-MSH was shown not to affect human sebocyte
proliferation (Zouboulis et al, 1998).
A major factor that has hampered basic research on human
sebocytes until recently is the lack of an easy-to handle sebocyte
culture model. Although human sebocyte culture models were
introduced in 1989 (Xia et al, 1989), the cultured primary cells are
predestined to differentiate by accumulating new fat droplets until
they burst and die. Recently, we have established a human
sebaceous gland cell line, SZ95, that was immortalized by
transfecting primary human facial sebocytes with the coding region
of the Simian virus-40 large T antigen (Zouboulis et al, 1999). This
cell line shows the morphologic, phenotypic, and functional
characteristics of normal human sebocytes.
By employing SZ95 sebocytes, we have set out to investigate the
expression of MC-Rs as a base for testing the hypothesis that
human sebocytes are target cells for a-MSH. After having
determined the MC-R expression pro®le in SZ95 sebocytes,
MC-1R expression was con®rmed in the sebaceous unit of adult
human skin. In order to assess the relevance of MC-1R expression
in sebocytes we ®nally investigated whether a-MSH can modulate
secretion of IL-8, an important chemoattractant for in¯ammatory
cells.
MATERIALS AND METHODS
Cell culture SZ95 sebocytes were maintained in Sebomed basal
medium supplemented with human epidermal growth factor (5 ng per
ml), 10% fetal bovine serum (FBS) (all from Biochrom, Berlin,
Germany), 1% glutamine, and 1% penicillin/streptomycin (both from
BioWhittaker, Walkersville, MD) in a humidi®ed atmosphere of 5%
CO2 at 37°C unless otherwise stated. Normal human neonatal
melanocytes and human dermal ®broblasts were purchased from
BioWhittaker and were cultured according to the manufacturer's
instructions. The melanoma cell line A375 was obtained from ATCC
and maintained in RPMI 1640 (Biochrom) supplemented with 10%
FBS, 1% glutamine, and 1% penicillin/streptomycin.
RNA extraction, reverse transcription polymerase chain reaction
(RT-PCR), and sequencing For all experiments, SZ95 sebocytes
were maintained in chemically de®ned Sebomed complete medium to
exclude the potential in¯uence of FBS. Total RNA from SZ95 sebocytes
and normal human melanocytes was isolated using the RNeasy kit from
Qiagen, Santa Clarita, CA. The RNA obtained was routinely digested
with DNAse (Promega, Madison, WI) to ensure complete absence of
genomic DNA. PCR ampli®cation was performed with REDTaq
polymerase (Sigma, Taufkirchen, Germany) and commercially synthe-
sized HPLC-puri®ed primers (Gibco-BRL, Gaithersburg, MD). The
sequences of the primer pairs and the sizes of their ampli®cation products
are given in Table I. The thermocycler protocols were the same as
previously reported by us (Bhardwaj et al, 1997; Hartmeyer et al, 1997).
The Px reaction mixture contained 10 mM Tris-HCl (pH 8.3), 50 mM
KCl, 1.1 mM MgCl2 0.01% gelatin, 0.05 V REDTaq DNA polymerase
(all from Sigma, St. Louis, MO) and 0.2 mM dNTP. Samples of RNA
that yielded ampli®cation products without prior reverse transcription
were excluded. PCR products were separated electrophoretically on
1.5%±2% TAE-agarose gels, stained with ethidium bromide, and
photographed under ultraviolet. The positive controls for MC-2R, MC-
3R, MC-4R, and MC-5R were derived from genomic DNA that was
prepared from human dermal ®broblasts by routine protocols. The
resulting positive bands from SZ95 sebocytes (MC-1R) were puri®ed
using a gel extraction kit (Qiagen), cloned into pGEM-T easy vectors
(Promega), and sequenced (4base lab, Reutlingen, Germany).
Immuno¯uorescence SZ95 sebocytes were seeded in Sebomed basal
medium into eight-well Laboratory-Tek Permanox chamber slides
(Nalge Nunc, Naperville, IL) at a density of 10,000 cells per well. Cells
were then grown for an additional 1±2 d to ensure suf®cient adherence
to the slides. They were ®xed with 4% paraformaldehyde for 30 min and
nonspeci®c binding was blocked with 5% donkey serum for 1 h. Then,
cells were incubated with the MC-1R antibody (1±10 mg per ml) for
1 h. Slides were washed with phosphate-buffered saline (PBS) and
incubated with a donkey anti-rabbit antibody conjugated with Texas
Red (1:100; Dianova). All procedures were performed at room
temperature. After ®nal washing the slides were mounted in Mowiol
(Hoechst, Frankfurt, Germany) and stored until use. Cells were imaged
and examined with a ¯uorescence microscope (Leica DMRD/RXA,
Leica Mikroskopie und Systeme, Wetzlar, Germany). Red ¯uorescence
was excited using the TX2 ®lter (BP 560/40 nm). Emission was
measured at 645 6 75 nm. In the negative controls cells were incubated
with preimmune serum or in the absence of the primary antibody.
Generation for an anti-human MC-5R antibody The antibody was
raised against the N-terminal region of the human MC-5R by
immunizing Swedish loop rabbits by intramuscular injections with
thyroglobulin-conjugated peptides in the presence of Freund's adjuvant.
The rabbits were given a booster of 1.1 mg of the conjugate in complete
Freund's adjuvant. The booster was then repeated twice with a 2 wk
interval with 0.8 mg of the conjugate and incomplete Freund's adjuvant.
Serum was collected 2 wk after the last booster. Preimmune serum had
been obtained before the immunization. The peptide NLSGPN-
VKNKSSPC corresponding to the amino acids 20±33 of the N-terminal
domain of the human MC-5R was made and conjugated by Medprobe,
Oslo, Norway. The speci®city of the serum to the peptide was
con®rmed by enzyme-linked immunosorbent assay (ELISA) against the
preimmune serum and a human MC-1R antiserum made by Xia et al
(1995).
Immunohistochemistry Samples of human adult skin (n = 6) derived
from patients undergoing routine surgery for therapeutic and diagnostic
reasons were examined. They were from various body sites including the
face and scalp. The positive control for MC-1R immunohistochemistry
consisted of a primary cutaneous human melanoma. For MC-5R
immunostaining, human prostate tissue was used as a positive control,
kindly provided by the Department of Pathology, University of MuÈnster.
Specimens were either cryo®xed in liquid nitrogen or ®xed in 7%
buffered paraformaldehyde, dehydrated, and embedded in parablast.
Parablast-embedded sections and cryosections were mounted on Tissue-
Tek (Mikrom, Walldorf, Germany). Parablast-embedded sections were
deparaf®nized, microwave-treated and quenched for endogenous
peroxidase activity, and blocked with 2% bovine serum albumin for
30 min at room temperature as described previously (BoÈhm et al, 1999a).
Table I. Primer sets used in RT-PCRa
Gene/Accession number Gene product Primer (F, forward; B, backward) Size Reference
MC1R/AF326275 MC-1R F: 5¢-GCCACCATCGCCAAGAACC-3¢ 416 Hartmeyer et al (1997)
B: 5¢-ATAGCCAGGAAGAAGACCA-3¢
MC2R/Z25470b MC-2R F: 5¢-CTGCATTTCTTGGATCT-3¢ 380 Hartmeyer et al (1997)
B: 5¢-AAGCTGCACATGGATGC-3¢
MC3R/NM019888 MC-3R F: 5¢-CGGTGGCCGACATGCTGGTAAGTG-3¢ 366 Hartmeyer et al (1997)
B: 5¢-TGAGGAGCATCATGGCGAAGAACA-3¢
MC4R/NM005912 MC-4R F: 5¢-CAATAGCCAAGAACAAGAATC-3¢ 566 Hartmeyer et al (1997)
B: 5¢-GACAACAAAGACGCCAATCAG-3¢
MC5R/NM005913b MC-5R F: 5¢-CATTGCTGTGGAGGTGTTTCT-3¢ 357 Bhardwaj et al (1997)
B: 5¢-GCCGTCATGATGTGGTGGTAG-3¢
aSequences as deposited in the National Center for Biotechnology Information (NBCI) database under the given accession number. Size denotes the number of base pairs
of the ampli®cation product.
bNote that the mRNA sequence for MC2 is a colinear but truncated form of the MC-5R.
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The sections were incubated with the anti-MC-1R antibody at 1 mg per
ml, with the individually generated MC-5R antiserum at 1±10 mg per
ml, or with one commercially available anti-MC-5R antibody (Santa
Cruz Biotechnology, Santa Cruz, CA) at 0.1±2 mg per ml for 45 min.
After washing, sections were developed by an indirect immuno-
peroxidase technique using 3-amino-9-ethylcarbazole (Sigma,
Deisenhofen, Germany) as a chromogen. For negative controls the
primary antibody was omitted or substituted with preimmune serum.
Determination of IL-8 Cells were trypsinized and seeded into six-well
tissue culture plates at a density of 150,000 per well. On the next day,
cells were washed with PBS and the culture medium was switched to
Sebomed complete medium. After 3 d in culture the medium was
removed. The cells were gently washed once with PBS. Two milliliters of
fresh Sebomed complete medium supplemented with a-MSH at varying
concentrations (10±6±10±12 M), IL-1b (50 ng per ml), or both substances
were added per well. Cells were then incubated for 2 d. Culture
supernatants were collected and passed through a 0.2 mm ®lter to remove
any cell detritus. Aliquots were stored at ±70°C until use. IL-8 in the
culture supernatants was determined using an ELISA from R&D Systems,
Minneapolis, MN. Duplicate wells were used for each individual sample;
the detection limit was less than 10 pg per ml. Statistical signi®cance was
calculated by the two-sample independent-groups t test.
RESULTS
Expression of MC-1R speci®c transcripts in SZ95
sebocytes We ®rst determined the MC-R expression pro®le
on the RNA level in SZ95 sebocytes by using speci®c primers
against the ®ve known MC-Rs. RT-PCR of total RNA revealed
only the expression of MC-1R (Fig 1a), whereas all other
transcripts, namely the MC-2R, MC-3R, MC-4R, and MC-5R,
were absent (Fig 1b, c). To ascertain that the lack of MC-2R to
MC-5R transcripts in SZ95 sebocytes was not caused by
insuf®cient ampli®cation, positive controls (genomic DNA from
diploid human dermal neonatal ®broblasts) were included in all
reactions. As shown in Fig 1(b, c), these samples resulted in
ampli®cation products of the expected size as previously reported
(Bhardwaj et al, 1997; Hartmeyer et al, 1997). The detected MC-
1R ampli®cation product derived from RNA of SZ95 sebocytes
(416 bp) (Fig 1a) comigrated with the product derived from RNA
of normal human melanocytes, which are known to express MC-
1R (Mountjoy et al, 1992). As it is known that the MC-1R displays
a high polymorphism in man (Rana et al, 1999) and the primers
used for RT-PCR (nucleotide positions 181±596) span a region
with known variants, the ampli®cation product of SZ95 sebocytes
was sequenced. It was identical to the original sequence of MC-1R
as published by Mountjoy et al (1992) (data not shown).
Detection of MC-1R immunoreactivity on the surface of
SZ95 sebocytes We next investigated the association of MC-
1R expression on the RNA level with surface expression of the
receptor in SZ95 sebocytes. Immunostaining of SZ95 sebocytes
was performed using an af®nity-puri®ed anti-MC-1R antibody
directed against the amino acids 2±18 of the N-terminal domain of
the human MC-1R (BoÈhm et al, 1999a; 1999b). As a positive
control, A375 melanoma cells, which are known to express MC-
1R (Siegrist et al, 1997), were included in these studies. Cells were
®xed with 4% paraformaldehyde without permeabilization. This
®xation method con®rmed the presence of surface MC-1R
immunoreactivity in both A375 melanoma cells and SZ95
sebocytes (Fig 2a, c). Both cell lines exhibited a punctate or
granular staining pattern. About 90% of A375 melanoma cells per
viewing ®eld exhibited MC-1R immunostaining, whereas the
percentage of SZ95 sebocytes staining positively was lower and
ranged between 40% and 60%. Interestingly, whereas in SZ95
sebocytes the punctate MC-1R immunostaining was diffuse and
occasionally accentuated in the cell periphery (Fig 2a), MC-1R
immunoreactivity in A375 melanoma cells was almost exclusively
located in focal areas opposing the nucleus (Fig 2c). Preimmune
serum or omission of the primary antibody, in contrast, did not
result in any immunostaining (Fig 2b, d).
Expression of MC-1R but not MC-5R immunoreactivity in
sebaceous glands in situ To assess the signi®cance of MC-1R
expression in SZ95 sebocytes, we performed immunohisto-
chemistry on normal adult human skin. As it has recently been
Figure 1. Expression of MC-1R-speci®c transcripts in SZ95
sebocytes as shown by RT-PCR. Total RNA from SZ95 sebocytes
(lane 2) was reverse transcribed and ampli®ed with primers against MC-
1R (a), MC-2R, MC-3R, MC-4R (b), and MC-5R (c). Positive
controls (lane 1) consisted of RNA from normal human melanocytes (for
MC-1R) and genomic DNA from normal human dermal ®broblasts (for
MC-2R, MC-3R, MC-4R, and MC-5R). Negative controls for the
MC-1R RT-PCR consisted of a contamination control using total
RNA from SZ95 sebocytes without reverse transcription (lane 3) and
substitution of the template with H2O (lane 4).
VOL. 118, NO. 3 MARCH 2002 HUMAN SEBOCYTES EXPRESS MELANOCORTIN-1 RECEPTORS 535
demonstrated that MC-5R knockout mice suffer from a defect in
water repulsion due to reduced sebaceous sebum secretion (Chen
et al, 1997), we also performed immunohistochemical studies for
the MC-5R. Sebaceous glands displayed MC-1R immuno-
reactivity in almost all sebocytes, but immunostaining was most
prominent in undifferentiated peripheral cells and in the central
more differentiated cells immunostaining was much less intense and
occasionally absent (Fig 3a). MC-1R immunostaining was mostly
detected in the cytoplasm of the sebocytes and, to a lesser extent, on
the surface of the cells. In accordance with previously reported
®ndings (BoÈhm et al, 1999a), MC-1R immunoreactivity was also
detected in secretory eccrine epithelia and in hair follicles whereas
interfollicular epidermis was mostly nonreactive (data not shown).
Omission of the primary antibody, substitution with preimune
serum, or preincubation of the anti-MC-1R antibody with the
immunogenic peptide used for generation of the MC-1R antibody
did abrogate staining (Fig 3b). Immunostaining of a primary
cutaneous human melanoma that was used as a positive control
revealed moderate MC-1R immunoreactivity in the cytoplasm of
the tumor cells (data not shown), in accordance with our previous
®ndings (BoÈhm et al, 1999a). We next performed immuno-
histochemistry of skin sections with two commercially available
anti-MC-5R antibodies and one individually generated antibody.
MC-5R immunoreactivity could not be detected in cryostat nor in
paraf®n-embedded sections derived from normal human adult
corporal and facial skin (Fig 3c). Our failure to detect MC-5R
immunoreactivity in normal adult human skin was not due to the
nature of the anti-MC-5R antibody used as prostate tissue known
to express MC-5R (Van der Kraan et al, 1998) clearly revealed
immunostaining within the secretory epithelia (Fig 3d).
Preimmune serum, in contrast, did not produce any staining
(Fig 3e).
Modulation of IL-8 secretion by a-MSH in SZ95
sebocytes In order to assess the biologic signi®cance of MC-
1R being expressed in SZ95 sebocytes, we determined the effect of
a-MSH on the secretion of IL-8. This chemokine is a key
chemoattractant for neutrophils and other immune cells, which
play a crucial role in the in¯ammatory response of the
pilosebaceous unit in acne and related disorders. All experiments
were performed in the absence of FBS and to reduce potential
effects of nonspeci®ed substances on IL-8 secretion. In addition to
nontreated cells and cells treated with a-MSH alone at varying
concentrations (10±6±10±12 M), a known inducer of IL-8
(Kristensen et al, 1991), namely IL-1, was included.
Immunoreactive IL-8 was detected by ELISA in signi®cant
amounts (mean 6 SD = 1722.5 6 176.2 pg per ml) in culture
media of unstimulated SZ95 sebocytes, indicating constitutive
production (Fig 4a). a-MSH alone barely affected IL-8 secretion
by SZ95 sebocytes, although the observed inhibitory effect of
a-MSH at 10±9 M was statistically signi®cant (p-value 0.06)
(Fig 4a). As expected, IL-1b treatment upregulated the secretion
of IL-8 to 3371.26 6 366.9 pg per ml (Fig 4b). When a-MSH at
10±9 M was coincubated with IL-1b, it signi®cantly suppressed the
IL-1b-induced IL-8 release by 28.4% (2415.5 6 8.5 pg per ml;
p-value 0.02) (Fig 4b). In contrast, all other concentrations of
a-MSH (whether given alone or in combination with IL-1b) did
not affect IL-8 secretion signi®cantly.
DISCUSSION
In this report we have shown that human sebocytes in vitro and
in situ express MC-1R. Our results on MC-1R expression in
sebocytes were unexpected as studies in mice have demonstrated
that targeted disruption of the MC-5R gene resulted in a defect in
water repulsion and thermoregulation due to reduced production
of sebaceous lipids (Chen et al, 1997). Moreover, in situ
hybridization in mice revealed MC-5R transcripts in a number
of secretory epithelia including those of the preputial gland,
prostate, lacrimal gland, and Harderian gland (Chen et al, 1997; Van
der Kraan et al, 1998). Recently, Thiboutot and coworkers also
reported that dissected human sebaceous glands express MC-5R as
shown by RT-PCR as well as by Western immunoblotting using
an MC-R5 antiserum raised in chicken (Thiboutot et al, 2000).
This antibody was directed against the same epitope of human MC-
5R that we chose for generation of our antiserum. By means of
their MC-5R antiserum, the latter authors observed MC-5R
immunoreactivity in sebaceous glands, sebaceous ducts, hair
follicles, epidermis, eccrine glands, endothelial cells, and ®broblasts
of cryostat sections from normal human facial skin. In contrast, we
were unable to detect MC-5R but MC-1R expression was present
in SZ95 sebocytes in vitro and sebocytes in situ. MC-1R expression
was not con®ned to the RNA level in SZ95 sebocytes but could
also be detected by immuno¯uorescence studies and immuno-
Figure 2. Visualization of MC-1R immuno-
reactivity on the surface of SZ95 sebocytes
by immuno¯uorescence. Cells were ®xed with
paraformaldehyde and stained with an anti-MC-
1R antibody directed against the amino acids 2±
28 of the N-terminal domain of MC-1R. Bound
antibodies were visualized using a Texas-Red-
conjugated secondary antibody. The staining
pattern of SZ95 sebocytes (a) was compared with
that of A375 melanoma cells, which are known to
express MC-1R (c). Note the diffuse punctate
immunostaining of SZ95 sebocytes (arrow)
compared to the focal staining pattern of A375
melanoma cells (arrow). Note also immunostaining
in the cell periphery of SZ95 sebocytes
(arrowhead). Preimmune serum did not produce
any speci®c staining in SZ95 sebocytes (b) or
A375 melanoma cells (d). Scale bar: 10 mm.
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histochemistry in SZ95 sebocytes and in sebaceous glands.
Interestingly, the surface MC-1R staining pattern differed between
SZ95 sebocytes and A375 melanoma cells. In contrast to SZ95
sebocytes MC-1R staining in A375 melanoma cells was con®ned to
distinct areas, which supports earlier investigations on Cloudman
mouse melanoma cells that displayed a nonrandom and patchy
distribution of MSH binding sites (Varga et al, 1976). It is possible
that the latter ®nding is related to autonomous secretion of a-MSH
and ACTH, which both bind to the MC-1R and thus may partly
abrogate binding of the anti-MC-1R antiserum. As it has been
shown that MSH binding sites correlate with pigmentation
(Kameyama et al, 1988), the MC-1R staining pattern of the
amelanotic A375 melanoma cell line, on the other hand, may also
indicate a relatively low expression level of MC-1R. Regarding
our immunohistochemical studies immunoreactivity for MC-1R
was con®rmed in sebocytes in situ. Ultrastructural studies by
immunoelectron microscopy have further shown that MC-1R
immunoreactivity in seboytes in situ is located both on the cell
surface and intracellularly in tubular endosomes (StaÈnder et al,
2002). Most of the in situ MC-1R immunoreactivity in human
sebocytes, however, was found within the cytoplasm, suggesting
that these cells do not produce POMC or POMC-derived peptides
(Slominski et al, 1993 and our own unpublished ®ndings). The
surprisingly weak immunoreactivity of MC-1R in human inter-
follicular epidermis as previously reported (BoÈhm et al, 1999a) may
indicate that only a limited number of receptors are available for the
anti-MC-1R antiserum and most of the MC-1Rs are complexed
with MSH or ACTH, which are produced by both keratinocytes
and melanocytes. In light of the discrepancies in the detected MC-
R expression pro®le in sebocytes between our study and that by
Thiboutot et al (2000) it is necessary to dissect the nature of these
differences in more detail. First, the primer sets against all examined
MC-Rs in our study and the one by Thiboutot et al (2000) were
different. With regard to MC-1R, Thiboutot et al (2000) neither
included a positive RT-PCR control in their studies nor continued
with immunohistochemical studies on MC-1R. Second, we have
used a uniform sebocyte population, whereas the RNA preparation
from microdissected human sebaceous glands in combination with
RT-PCR as performed by Thiboutot et al (2000) does not exclude
contamination by other cell types. On the other hand, although we
have con®rmed the immunoreactivity of our anti-MC-5R anti-
body by demonstrating immunostaining of prostate epithelia, the
MC-5R antibody generated by Thiboutot et al (2000) may be more
sensitive than our own, especially in combination with the applied
metal enhancer kit.
Our studies on chemokine release by SZ95 sebocytes have
con®rmed our previous reports that sebocytes secrete IL-8 in a
constitutive manner.1,2 IL-8 may serve as the chemokine that is
responsible for the attraction of in¯ammatory cells to the sebaceous
gland and the initiation of the in¯ammatory process, e.g., in acne.
IL-8 has been shown to be induced in SZ95 sebocytes by
Propionibacterium acnes, IL-1a, lipopolysaccharides, as well as
calcitonin gene-related peptide, and to be inhibited by linoleic
acid.1±3 Interestingly, a-MSH at 10±9 M was found to partially
abrogate IL-1b-induced IL-8 secretion in SZ95 sebocytes. By
Figure 3. Detection of MC-1R but not MC-
5R immunoreactivity in the human
sebaceous gland in situ. Deparaf®nized sections
from normal human adult corporal skin and
human prostate gland (the latter serving as a
positive control for MC-5R) were incubated with
antibodies against MC-1R or MC-5R,
respectively. Bound antibodies were visualized by
the immunoperoxidase technique. Sebaceous
gland showing intracytoplasmic MC-1R staining
mainly in the undifferentiated peripheral cells
(arrow), 4003 (a); negative control of a normal
skin section, i.e., preincubation of the primary
antibody with the immunogenic peptide in
excess, 4003 (b); lack of MC-5R
immunoreactivity in human sebaceous glands,
2003 (c); human prostate gland; note intracellular
MC-5R staining of secretory epithelia (arrow),
4003 (d); negative control using preimmune
serum instead of the anti-MC-5R antibody, 4003
(e). Scale bars: 50 mm (a, b, d, e) and 100 mm (c).
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2Seiffert K, Zouboulis ChC, Seltmann H, Granstein RD: Expression of
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agonists on cytokine production. Horm Res 53:102, 2000 (abstr.)
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Propionibacterium acnes does not in¯uence the interleukin-1a/interleu-
kin-8 cascade in immortalized human sebocytes in vitro. J Invest Dermatol
114:816, 2000 (abstr.)
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modulating IL-8 secretion, a-MSH could act as a modulator of
in¯ammatory responses of the pilosebaceous unit. Our ®ndings on
the modulatory activity of a-MSH on IL-8 release by IL-1b-
stimulated SZ95 sebocytes are in accordance with our recent
studies showing that IL-8 secretion by human dermal ®broblasts
can be modulated by a-MSH (BoÈhm et al, 1999c). As it has been
shown that the immunomodulatory activity of a-MSH can partly
be abrogated by pharmacologic blockade with butoxamine, a b2-
adrenergic receptor antagonist (Ichiyama et al, 1999), however, it
remains to be determined whether other receptors than MC-1R
are involved in eliciting the biologic responses by a-MSH in
human sebocytes.
In summary, we have shown here that sebocytes in vitro and in
situ express MC-1R and that a-MSH can partially abrogate the
inductive effects of IL-1b on IL-8 secretion by SZ95 sebocytes.
Detection of the MC-1R in SZ95 sebocytes as presented in this
paper provides the base for ongoing studies in our laboratory to
clarify whether a-MSH can affect lipogenesis in human sebocytes.
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